ALEC
Price
$2.59Alerts
Change
+$0.05 (+1.97%)
Updated
Nov 16, 01:47 PM (EDT)
Capitalization
255.69M
106 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$1.86Alerts
Change
-$0.30 (-13.82%)
Updated
Nov 16, 04:59 PM (EDT)
Capitalization
394.7M
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALEC vs EDIT

ALEC vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 28, 2026

Which Stock Would AI Choose? Alector (ALEC) vs. Editas Medicine (EDIT) Stock Comparison

Key Takeaways

  • Both ALEC and EDIT are clinical-stage biotechnology companies trading in the low single digits, but they pursue fundamentally different platforms and near-term catalysts.
  • Alector is rebuilding after a late-stage trial setback, while Editas Medicine is advancing a newly cleared first-in-human gene-editing program, giving EDIT a clearer near-term catalyst.
  • Editas holds a larger cash runway relative to its burn and recently received clinical clearance in Australia, supporting a more constructive sentiment shift in recent weeks.
  • Alector faces a reset valuation and mixed analyst ratings as it pivots toward earlier-stage "BBB-shuttle" (blood-brain barrier) therapeutics.
  • Relative performance and risk profiles diverge: EDIT offers a defined 2027 data readout, while ALEC carries longer-dated, earlier-stage optionality.
  • For deeper coverage, explore ALEC Major News and ALEC Today's Price Move, plus EDIT Major News and EDIT Today's Price Move.
  • To see how automated strategies are positioning across names like these, visit Trending AI Robots.

Introduction

Investors comparing ALEC and EDIT are weighing two distinct bets within biotechnology. Alector, Inc. develops immuno-neurology therapies for neurodegenerative diseases, while Editas Medicine, Inc. is a pioneer in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing. Both are pre-revenue, cash-burning companies whose stock prices are driven largely by clinical data and financing decisions rather than earnings. This stock comparison is most relevant to biotech-focused traders and risk-tolerant investors assessing relative performance, market positioning, and the timing of potential catalysts in the current environment.

ALEC Overview and Recent Performance

Alector, Inc. is a clinical-stage biopharmaceutical company advancing therapies that aim to counter neurodegeneration by engaging the immune system. Its share price has been under pressure in recent months after its lead program, latozinemab, failed to meet its primary endpoint in the Phase 3 INFRONT-3 trial in frontotemporal dementia. The company subsequently terminated that program and implemented a substantial workforce reduction of roughly 49%, refocusing resources on an earlier-stage pipeline and novel "BBB-shuttle" (blood-brain barrier) delivery approaches.

In recent weeks, analyst sentiment on ALEC has remained mixed. Several firms have maintained Hold or Sell ratings with sharply reduced price targets, while a few have turned more constructive on the pipeline reset. The stock trades near the low end of its 52-week range, and insider selling activity has added to a cautious tone. Alector's near-term story centers on cost discipline and early-pipeline optionality rather than an imminent clinical catalyst, which has kept relative performance subdued.

EDIT Overview and Recent Performance

Editas Medicine, Inc. is a genome-editing company that has pivoted to an in vivo (within the living organism) CRISPR strategy. After discontinuing its reni-cel program in late 2024 and cutting its workforce, the company refocused on EDIT-401, an experimental one-time gene-editing therapy designed to reduce LDL ("bad") cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). In recent weeks, Editas received approval to initiate the Phase 1/2 STRIVE clinical trial in Australia, a milestone that marked its return to the clinic.

That clearance prompted at least one major firm to upgrade EDIT, citing a potential value inflection as clinical proof-of-concept data arrives in 2027. The company reported roughly $211.6 million in cash and investments as of mid-2026 and has guided that its runway extends into the second half of 2028. Preclinical results showing approximately 90% or greater reductions in LDL cholesterol and related lipoproteins have underpinned renewed investor interest, supporting stronger relative momentum than Alector over the same period.

Trending AI Robots

For traders seeking a systematic, data-driven perspective on names like ALEC and EDIT, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant automated strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistics. Rather than listing every bot, Tickeron highlights only those best suited to prevailing market conditions. Because each bot operates with a distinct approach, reviewing the curated selection can help traders understand how algorithmic systems are currently positioned across volatile, catalyst-driven biotech names. Explore the Trending AI Robots to see which strategies are adapting to today's market.

Head-to-Head Comparison

Although both companies are speculative biotech investments, their market positioning differs sharply. Alector operates in neurodegeneration, an area with high unmet need but lengthy, high-risk development timelines; its setback pushed meaningful value creation further into the future. Editas operates in genetic medicine with a single, sharply defined lead program and a near-term, data-rich catalyst path through 2027.

On momentum, Editas has benefited from a concrete positive development—clinical clearance and an analyst upgrade—while Alector is still absorbing the fallout from a failed trial and a valuation reset. On financial stability, Editas' stated cash runway into 2028 compares favorably with Alector's leaner, earlier-stage repositioning. Risk factors also diverge: Alector's exposure is concentrated in unproven early-stage science and delivery technology, whereas Editas faces execution risk in a first-in-human trial in a competitive cholesterol market. Sector exposure is another contrast, with neurodegeneration and gene editing carrying different regulatory, competitive, and reimbursement dynamics.

Tickeron AI Verdict

Based on observable factors such as trend consistency, catalyst timing, financial runway, and recent sentiment, Tickeron's AI would likely lean toward EDIT in the current environment. Editas pairs a clearer near-term catalyst—clinical dosing and a 2027 data readout—with a longer cash runway and a constructive recent upgrade. Alector's early-stage repositioning carries genuine optionality but offers fewer near-term signposts for trend confirmation. This assessment is probabilistic rather than definitive: both names remain high-risk, and shifts in clinical data, financing, or broader biotech sentiment could quickly change the relative picture.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
ALEC vs. EDIT commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a Hold and EDIT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALEC with price predictions
Nov 13, 2026

ALEC saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 64 similar instances where the indicator exited the overbought zone. In 58 of the 64 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.

ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 218 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.498). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EDIT with price predictions
Nov 13, 2026

EDIT sees MACD Histogram crosses below signal line

EDIT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 125 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALEC vs EDIT: Fundamental Ratings
ALEC
EDIT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3572
P/E GROWTH RATING
1..100
9330
SEASONALITY SCORE
1..100
2985

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALEC's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for EDIT (53). This means that ALEC’s stock grew somewhat faster than EDIT’s over the last 12 months.

ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ALEC’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as ALEC (100). This means that EDIT’s stock grew similarly to ALEC’s over the last 12 months.

ALEC's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for EDIT (72). This means that ALEC’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's P/E Growth Rating (30) in the Biotechnology industry is somewhat better than the same rating for ALEC (93). This means that EDIT’s stock grew somewhat faster than ALEC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALECEDIT
RSI
ODDS (%)
Bearish Trend 4 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 14 days ago
87%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
81%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (ALEC: $2.54 vs. EDIT: $2.17)
Brand notoriety: ALEC and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALEC: 54% vs. EDIT: 107%
Market capitalization -- ALEC: $255.69M vs. EDIT: $394.7M
ALEC [@Biotechnology] is valued at $255.69M. EDIT’s [@Biotechnology] market capitalization is $394.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALEC’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).

  • ALEC’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, ALEC is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALEC’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ALEC’s TA Score: 5 bullish, 5 bearish.
  • EDIT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALEC is a better buy in the short-term than EDIT.

Price Growth

ALEC (@Biotechnology) experienced а +10.92% price change this week, while EDIT (@Biotechnology) price change was -15.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

ALEC is expected to report earnings on Mar 02, 2027.

EDIT is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ALEC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALEC
1D Price
Change %
ALEC100%
+3.67%
EDIT - ALEC
49%
Loosely correlated
+1.40%
BCYC - ALEC
47%
Loosely correlated
-2.32%
VYGR - ALEC
43%
Loosely correlated
+1.76%
ARVN - ALEC
43%
Loosely correlated
-0.73%
PRTA - ALEC
42%
Loosely correlated
-0.85%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UPSX5.770.22
+3.96%
Tradr 2X Long UPST Daily ETF (UPSX)
FNDA36.210.04
+0.11%
Schwab Fundamental U.S. Small Company ETF (FNDA)
ITWO42.59-0.14
-0.33%
ProShares Russell 2000 High Income ETF (ITWO)
SEEM34.98-0.28
-0.80%
SEI Select Emerging Markets Equity ETF (SEEM)
EGGS28.51-0.67
-2.29%
NestYield Total Return Guard ETF (EGGS)